Comprehensive Bioinformatics Analysis Reveals Kirsten Rat Sarcoma Virus Oncogene (KRAS) as the Potential Biomarker of Esophageal Carcinoma

In the current study, the expression of the Kirsten rat sarcoma virus oncogene (KRAS) in esophageal carcinoma (ESCA) was examined for its medical and therapeutic relevance. ESCA has a 20% five-year survival rate, placing it seventh in the world in terms of overall rate of mortality. GEPIA2, UALCAN, OncoDB, cBioPortal, STRING, DAVID, and TIMER2 databases are among the bioinformatics tools used to conduct this investigation. According to the analysis, KRAS was significantly (P < 0.05) elevated in ESCA samples in contrast to normal tissues, demonstrating that it might play an active role in the proliferation of malignancies. Additionally, the study based on several clinicopathological features showed that KRAS were significantly up-regulated. ESCA patients had a worse overall survival rate (OS) as KRAS was significantly overexpressed. Besides this, the study carried out analyses of drug sensitivity, enrichment, and promoter methylation to inquire about their relationships to KRAS expression in ESCA. The KRAS mutation was demonstrated to have a significant impact on the progression of ESCA via the genetic changes that were observed using cBioPortal. In conclusion, the comprehensive analysis of the findings emphasizes the significance of KRAS up-regulation in the development of ESCA and its potential as a potential biomarker.